Monosol sues BioDelivery over pain treatment
17-01-2017
Teva sued over opioid overdose drug
25-10-2016
21-12-2021
Pavel Kapysh / Shutterstock.com
A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ (BDSI) opioid medication Belbuca (buprenorphine), but invalidated others.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
BioDelivery Sciences, Belbuca, US District Court for the District of Delaware
Monosol sues BioDelivery over pain treatment
17-01-2017
Teva sued over opioid overdose drug
25-10-2016